Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06373406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of MHB036C for Advanced Solid Tumor

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 2024 to Dec 2025v3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2024 to Dec 2026
    • Start date: May 18, 2023 to May 26, 2023
    • Site details revised
  2. Study title shortened, about 2 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.
Trial Details
NCT Number NCT06373406
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions
(from sponsor)		 Advanced Solid Tumor
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov